NASDAQ:NEXI

NexImmune (NEXI) Stock Forecast, Price & News

$0.32

+0.03 (+10.32%)

(As of 05/26/2023 ET)

Compare

Today's Range: $0.27
▼
$0.32
50-Day Range: $0.28
▼
$0.47
52-Week Range: $0.19
▼
$2.68

Volume: 137,202 shs
Average Volume: 474,731 shs
Market Capitalization: $8.36 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.33

NexImmune MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 939.4% Upside
$3.33 Price Target
Short Interest: Healthy
1.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.36
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$164,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.65) to ($0.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
NexImmune has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.33, NexImmune has a forecasted upside of 939.4% from its current price of $0.32.
Amount of Analyst Coverage
NexImmune has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.34% of the float of NexImmune has been sold short.
Short Interest Ratio / Days to Cover
NexImmune has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NexImmune has recently decreased by 0.61%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
NexImmune does not currently pay a dividend.
Dividend Growth
NexImmune does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NEXI.

2.4

News and Social Media Coverage

News Sentiment
NexImmune has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for NexImmune this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for NEXI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
1 people have added NexImmune to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NexImmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $164,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
17.80% of the stock of NexImmune is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 32.45% of the stock of NexImmune is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NexImmune are expected to grow in the coming year, from ($0.65) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NexImmune is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NexImmune is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NexImmune has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NexImmune (NASDAQ:NEXI) Stock

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

NEXI Stock News Headlines

May 22, 2023 | finance.yahoo.com

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

May 16, 2023 | finanznachrichten.de

NexImmune, Inc.: NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

May 27, 2023 | Behind the Markets (Ad)

AI Creates New Cancer Drug - In Just 30 Days!

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

May 15, 2023 | msn.com

Recap: NexImmune Q1 Earnings

May 15, 2023 | finance.yahoo.com

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

April 26, 2023 | finance.yahoo.com

NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting

April 23, 2023 | americanbankingnews.com

NexImmune (NASDAQ:NEXI) Trading 4.3% Higher

April 5, 2023 | benzinga.com

NexImmune Stock (NASDAQ:NEXI), Guidance and Forecast

May 27, 2023 | Legacy Research (Affiliate) (Ad)

Stocks are for suckers – try this instead

This has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...

April 2, 2023 | finanznachrichten.de

NexImmune, Inc.: NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

April 1, 2023 | americanbankingnews.com

NexImmune, Inc. (NASDAQ:NEXI) Director Sol J. Barer Acquires 400,000 Shares

March 30, 2023 | bizjournals.com

Maryland biotech Salubris Biotherapeutics clinches $35M investment for R&D

March 28, 2023 | finance.yahoo.com

NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 28, 2023 | bizjournals.com

Gaithersburg biotech Salubris Biotherapeutics clinches $35M investment for R&D

February 24, 2023 | finance.yahoo.com

NexImmune Shares Are Ripping Today - Read Why

February 16, 2023 | marketwatch.com

NexImmune Up 40% to 57c After Favorable Preclinical Data on T-Cell Therapy to Reduce Tumors

February 16, 2023 | msn.com

NexImmune stock surges ~55% on preclinical data linked to T cell response

February 16, 2023 | finance.yahoo.com

NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

January 18, 2023 | finance.yahoo.com

NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform to Treat Viral Diseases

December 31, 2022 | finance.yahoo.com

NexImmune, Inc. (NEXI) Stock Historical Prices & Data - Yahoo Finance

December 7, 2022 | finanznachrichten.de

NexImmune, Inc.: NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update

November 21, 2022 | finance.yahoo.com

NexImmune laying off 30% of workers following cuts to clinical programs

November 21, 2022 | finance.yahoo.com

Sol Barer Is The Independent Chairman of the Board of NexImmune, Inc. (NASDAQ:NEXI) And They Just Picked Up 5.7% More Shares

November 18, 2022 | benzinga.com

Massive Insider Trade At NexImmune

November 16, 2022 | finance.yahoo.com

Analyst Downgrades NexImmune After Going Back To Preclinical Stage

November 15, 2022 | finance.yahoo.com

Exicure Flags Bankruptcy Concerns, Shares Fall

November 15, 2022 | finance.yahoo.com

NexImmune Shifts Focus On AIM Direct Injection Platform, Potential Candidates In Oncology & Autoimmune Diseases

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

NEXI Company Calendar

Last Earnings: 3/28/2023
Today: 5/27/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NEXI
CUSIP: N/A
CIK: 1538210
Web: www.neximmune.com
Phone: 301-825-9810
Fax: N/A
Employees: 74
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.33
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +939.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -143.12%
Return on Assets: -115.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.74
Quick Ratio: 3.74

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.90 per share
Price / Book: 0.36

Miscellaneous

Outstanding Shares: 26,080,000
Free Float: 21,436,000
Market Cap: $8.36 million
Optionable: Not Optionable
Beta: 2.31

Key Executives

Ms. Kristi Jones R.Ph. (Age 59)
CEO, Pres & Director
Comp: $520.87k

Mr. John Trainer M.B.A. (Age 48)
Chief Financial Officer
Comp: $514.67k

Dr. Jerome Bernard Zeldis M.D. (Age 72)
Ph.D., Exec. VP of R&D
Comp: $405.79k

Dr. Robert Douglas Knight M.D. (Age 71)
Chief Medical Officer
Comp: $454.77k

Dr. Mathias Oelke Ph.D. (Age 54)
Chief Scientific Officer

Dr. Jeffrey S. Weber M.D.
Ph.D., Chief Scientific Advisor, Co-Chairman of Scientific Advisory Board and Member of AI & ID SAB

Mr. Karen Haslbeck
Head of HR

Dr. Daniel P. Bednarik
Sr. VP of Molecular Engineering & Protein Design

Mr. Chad Rubin
Sr. VP of Corp. Affairs

Dr. Jack A. Ragheb M.D.
Ph.D., Sr. VP of Translational Science

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NEXI Stock - Frequently Asked Questions

Should I buy or sell NexImmune stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NexImmune in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NEXI shares.
View NEXI analyst ratings or view top-rated stocks.
What is NexImmune's stock price forecast for 2023?: 4 brokers have issued 1 year price objectives for NexImmune's stock. Their NEXI share price forecasts range from $2.00 to $5.00. On average, they expect the company's share price to reach $3.33 in the next year. This suggests a possible upside of 939.4% from the stock's current price.
View analysts price targets for NEXI or view top-rated stocks among Wall Street analysts.
How have NEXI shares performed in 2023?: NexImmune's stock was trading at $0.2431 at the beginning of the year. Since then, NEXI shares have increased by 31.9% and is now trading at $0.3207.
View the best growth stocks for 2023 here.
When is NexImmune's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our NEXI earnings forecast.
How were NexImmune's earnings last quarter?: NexImmune, Inc. (NASDAQ:NEXI) released its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $0.07.
When did NexImmune IPO?: (NEXI) raised $75 million in an IPO on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO.

What is NexImmune's stock symbol?: NexImmune trades on the NASDAQ under the ticker symbol "NEXI."
Who are NexImmune's major shareholders?: NexImmune's stock is owned by a number of institutional and retail investors. Top institutional investors include Slate Path Capital LP (3.55%), Citigroup Inc. (3.06%), Raymond James & Associates (1.23%), First Manhattan CO. LLC. (0.57%), Caprock Group LLC (0.40%) and Envestnet Asset Management Inc. (0.31%). Insiders that own company stock include Grant Verstandig, Jerome B Zeldis, Kristi Jones and Sol J Barer.
View institutional ownership trends.
How do I buy shares of NexImmune?: Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NexImmune's stock price today?: One share of NEXI stock can currently be purchased for approximately $0.32.
How much money does NexImmune make?: NexImmune (NASDAQ:NEXI) has a market capitalization of $8.36 million. The company earns $-62,510,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.
How can I contact NexImmune?: NexImmune's mailing address is 9119 GAITHER ROAD, GAITHERSBURG MD, 20877. The official website for the company is www.neximmune.com. The company can be reached via phone at 301-825-9810 or via email at crubin@soleburytrout.com.

This page (NASDAQ:NEXI) was last updated on 5/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial